Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies. The Finasteride Study Group.
The efficacy and safety profiles of finasteride were tested in 1,645 patients with benign prostatic hyperplasia (BPH) over a 12-month period. The following effects were observed: (1) a 60-80% reduction in serum dihydrotestosterone levels; (2) a 20% reduction in prostate volume; (3) significant increases in the maximum urinary flow rate compared with placebo; and (4) significant improvement in urinary symptoms, particularly obstructive symptoms. All effects were well maintained for the entire duration of the study. Finasteride had a good safety profile and was well tolerated.
Grino
P
P
Merck Sharp & Dohme Research Laboratories, Rahway, NJ 07065.
Stoner
E
E
D000368:Aged; D013196:Dihydrotestosterone / Q000097:blood; D004311:Double-Blind Method; D018120:Finasteride / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
D013196:Dihydrotestosterone; D018120:Finasteride; D017430:Prostate-Specific Antigen